BioSpecifics Technologies Corp
BioSpecifics Technologies — Investor Presentation (November 2016)
24 slides from BioSpecifics Technologies's investor presentation, Nov 14, 2016
Slide 1: Innovators in the development and commercialization of injectable collagenase
) —— ad \é \ < pale Innovators in the development & commercialization of _ INJECTABLE COLLAGENASE c —_ = We BioSpecifics November 2016
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, All statements other than statements of historical fact, including statements regarding
Slide 3: Originator of collagenase based-therapies
Originator of collagenase based-therapies Positive clinical results for CCH reported in 12 indications to date Profitable biopharma company with lean corporate structure and stock buy-back program Receives revenues from XIAFLEX® milestones, royalties on net sales, mark-up on COGS and sublicense inco
Slide 4: Pipeline
XIAFLEX® Pipeline [tetcaton | Prec | riaset | rimse2_ | phases | wartted | ttetones | Cupeyvers Contacte <r Ee fori erence Peyronie’s Disease Cellulite endo Enrollment complete in Phase 2b Endo is currently performing a commercial assessment BSTC reported positive, statistically Human Lipoma endo eS
Slide 5: Marketed XIAFLEX Indications
Marketed XIAFLEX Indications: Dupuytren’s Contracture & Peyronie’s Disease
Slide 6: XIAFLEX 3Q16 U.S. Net Sales and Future Growth Initiatives
XIAFLEX 3Q16 U.S. Net Sales and Future Growth Initiatives 3Q16 U.S. net sales were $47.7 million, a 19% increase vs. 3Q15 FUTURE GROWTH INITIATIVES: Broaden physician base with improved targeting to reach the most appropriate physicians Direct to consumer campaigns Dupuytren’s contracture print ads
Slide 7: Dupuytren's Contracture
XIAFLEX® for Dupuytren’s Contracture Definition & Key Complications Deforming condition of the hand in which one or more fingers contracts toward the palm Limits range of motion and impairs quality of life Affects between 3-9% of adult Caucasians Pre-treatment: Post-treatment: cz oe Source: Endo int
Slide 8: Peyronie's Disease
XIAFLEX® for Peyronie’s Disease Definition & Key Complications Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Associated with increased pain, painful erections, palpable plaque, penile deformity and erectile dysfunction Potential loss of self
Slide 9: Pipeline Indications
XIAFLEX® Pipeline Indications:
Slide 10: Uterine Fibroids
XIAFLEX® for Uterine Fibroids Phase 1 Trial to Begin in 1Q17 Definition & Key Complications U.S. Market Opportunity Encouraging Preclinical Data Benign tumors in the reproductive tract that contain large amounts of collagen Cause pelvic discomfort and pain, decreased fertility, pregnancy complicatio
Slide 11: Uterine Fibroids Phase 1 Trial Design
XIAFLEX® for Uterine Fibroids Phase 1 Trial Design Open-label dose escalation Phase 1 study in 15 female subjects treated prior to hysterectomy 3 groups Primary endpoint: Assess the safety and tolerability of CCH following a one-time injection directly into uterine leiomyomas at three doses under tr
Slide 12: Cellulite: Enrollment Complete in Phase 2b Study
XIAFLEX® for Cellulite Enrollment Complete in Phase 2b Study Skin dimpling as a result of collagen fibrous septae, occurring mainly on the buttocks, lower limbs, and abdomen Affects ~85-98% of post-pubertal females Phase 2b Study Design ~350 women (18+ years) Up to 3 treatment sessions of 0.84 mg/se
Slide 13: Cellulite: Positive Top-line Data from Phase 2a Study
XIAFLEX® for Cellulite Positive Top-line Data from Phase 2a Study Top-line data from Phase 2a study: 150 women received up to three treatment sessions of drug or placebo according to randomization (5 high-dose (0.84mg): 5 mid (0.48mg): 5 low (0.06mg): 3 placebo) Mid and high level XIAFLEX® doses dem
Slide 14: Adhesive Capsulitis
XIAFLEX® for Adhesive Capsulitis Potential to be Only FDA Approved Nonsurgical Therapy Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder Common available treatment options are often painful and can require anesthesia Long-term intensive physical thera
Slide 15: Human Lipomas
XIAFLEX® for Human Lipomas Potential to be Only FDA-Approved Pharmaceutical Therapy U.S. Market Opportunity Phase 2 Trial Design Encapsulated deposits of benign fat, often detected as bulges under the skin No FDA-approved pharmaceutical therapies available Offers an alternative to patients that may
Slide 16: Positive Top-Line Phase 2 Study Results
Positive Top-Line Phase 2 Study Results Single 0.58 mg Injection of CCH Primary endpoint: 81.3% reduction in visible surface area for CCH vs. 2.1% increase for placebo; 83.4% difference in favor of CCH (p<0.0001) 89.5% responder rate (showed a >50% decrease in lipoma visible surface area relative to
Slide 17: Lateral Hip Fat
XIAFLEX® for Lateral Hip Fat Definition & Complications Similar prevalence to cellulite Fat accumulation is common among woman particularly as they age Often very difficult to improve its appearance through exercise and diet alone Patients frequently avoid exercise and are unable to restrict their c
Slide 18: Plantar Fibromatosis
XIAFLEX® for Plantar Fibromatosis Definition & Complications ~200,000 patients in the U.S. Pain and disability caused by the thickening of the feet's deep connective tissue Formation of nodules or cords along tendons of the foot Patients often have Dupuytren’s disease, Peyronie’s disease and adhesiv
Slide 19: Additional Promising Unlicensed Indications
onal Promising Unlicensed Indications Capsular Contracture, Breast Hypertrophic Scars & Keloids Dercum’s Disease Knee Arthrofibrosis Urethral Strictures Source: Endo International pic Post-surgical complication that can deform the breast and cause pain Scars that form on the skin at site of injury O
Slide 20: Endo Partnership for Development and Commercialization of XIAFLEX
Endo Partnership for Development and Commercialization of XIAFLEX® >$101.7M Received as of September 30, 2016 $101.7M received in licensing, sublicensing, milestone, COGS, and royalty payments as of September 30, 2016 Low double digit royalties as % of net sales Future Payments Additional mark-up on
Slide 21: Strong IP Portfolio
Strong IP Portfolio Long-term patent protection for CCH Dupuytren’s Contracture Biologic Exclusivity until 2022 Drug product composition patent until 2028 Peyronie’s Disease Orphan Drug protection in U.S. until 2020 Drug product composition patent until 2028 Patents and Patent Applications Owned, co
Slide 22: Consistently Profitable Annually
Consistently Profitable Annually Financial Highlights (unaudited) For the nine months ended 09/30/16 09/30/15 7 Cash and equivalents, and investments $51,266,414 $ 32,824,471 Income Statement Revenues $19,630,307 $16,611,268 Other income 238,152 65,056 Costs and expenses (6,915,669) (6,062,469) Prov
Slide 23: Anticipated Upcoming Pipeline Milestones
Anticipated Upcoming Pipeline Milestones ENDO: Cosmetic Indications Cellulite O Announce top-line data from Phase 2b trial | BIOSPECIFICS: Medically Necessary Indications Uterine Fibroids* C1 Initiate clinical trial in 1017
Slide 24: \é \ < pale
& 4 EE ——— @ \é \ < pale Innovators in the development & commercialization of _ INJECTABLE COLLAGENASE weemam,., . BioSpecifics November 2016
BioSpecifics Technologies — Investor Presentation (November 2016) on 6ix